Scholarlink

Background <p>Administration of ketone bodies attenuated the severity of sepsis-induced muscle weakness in preclinical studies. Whether lipid-rich emulsions may likewise mitigate such muscle weakness by stimulating the endogenous ketogenic capacity remains uncertain, especially in relation to glucose, a critical suppressor of ketogenesis. This study investigated the ketogenic potential of parenteral nutrition rich in long- and/or medium-chain triglycerides with differing glucose content on sepsis-induced muscle weakness.</p> Methods <p>We used a parenterally fed murine model of prolonged sepsis-induced muscle weakness to investigate specific lipid mixtures in two consecutive studies. Septic mice receiving standard total parenteral nutrition (TPN) and healthy control (HC) animals were included as references in both studies. In a first study, septic mice received pure long-chain triglycerides (LCT) or long-chain triglycerides supplemented with glucose (gLCT). The second study compared a gLCT mixture to a mixed medium- and long-chain triglyceride emulsion supplemented with glucose (gMCT). After 5&#xa0;days of sepsis, markers of ketone body metabolism, muscle function, and muscle and liver metabolomics were measured.</p> Results <p>In study one, ketosis was undetectable with TPN-treatment, but substantially increased with pure LCT (median 1.39&#xa0;mmol/L, <i>p</i> &lt; 0.001). Supplemental glucose suppressed ketosis sixfold (median 0.24&#xa0;mmol/L, <i>p</i> &lt; 0.001). The sepsis-induced muscle weakness was exacerbated in LCT mice, while muscle force was comparable between TPN-treated and gLCT mice (TPN 60.9%; gLCT 60.9%; LCT 33.1% of HC 128.7&#xa0;mN/mm<sup>2</sup>, <i>p</i> &lt; 0.001). The decrease in muscle glycolytic metabolites in LCT mice relative to TPN-treated mice was attenuated by supplemental glucose. In study 2, unexpectedly, ketosis was similarly low in gLCT and gMCT mice (<i>p</i> = 0.1), and muscle force was equally reduced in all septic groups (TPN 68.1%; gLCT 74.0%; gMCT 65.9% of HC 105.9&#xa0;mN/mm<sup>2</sup>, <i>p</i> = 0.5) as compared to HC mice. Protein expression of the rate-limiting enzyme of ketogenesis, Hmgcs2, was suppressed in gMCT as compared to gLCT mice (<i>p</i> = 0.04).</p> Conclusions <p>Pure LCT infusion induced ketosis, but aggravated muscle weakness, which was attenuated by providing supplemental glucose. Combined with glucose, neither long-chain triglycerides nor mixed medium- and long-chain triglycerides were able to induce adequate ketosis or attenuate sepsis-induced muscle weakness.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

The impact of lipid-rich nutrition on ketogenesis and muscle weakness in sepsis

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年2月12日

查看全文
  • Caroline Lauwers,
  • Jan Gunst,
  • Soraya El Dawy,
  • Sarah Derde,
  • Lies Pauwels,
  • Inge Derese,
  • Sarah Vander Perre,
  • Greet Van den Berghe,
  • Michael P. Casaer,
  • Lies Langouche

摘要

Background

Administration of ketone bodies attenuated the severity of sepsis-induced muscle weakness in preclinical studies. Whether lipid-rich emulsions may likewise mitigate such muscle weakness by stimulating the endogenous ketogenic capacity remains uncertain, especially in relation to glucose, a critical suppressor of ketogenesis. This study investigated the ketogenic potential of parenteral nutrition rich in long- and/or medium-chain triglycerides with differing glucose content on sepsis-induced muscle weakness.

Methods

We used a parenterally fed murine model of prolonged sepsis-induced muscle weakness to investigate specific lipid mixtures in two consecutive studies. Septic mice receiving standard total parenteral nutrition (TPN) and healthy control (HC) animals were included as references in both studies. In a first study, septic mice received pure long-chain triglycerides (LCT) or long-chain triglycerides supplemented with glucose (gLCT). The second study compared a gLCT mixture to a mixed medium- and long-chain triglyceride emulsion supplemented with glucose (gMCT). After 5 days of sepsis, markers of ketone body metabolism, muscle function, and muscle and liver metabolomics were measured.

Results

In study one, ketosis was undetectable with TPN-treatment, but substantially increased with pure LCT (median 1.39 mmol/L, p < 0.001). Supplemental glucose suppressed ketosis sixfold (median 0.24 mmol/L, p < 0.001). The sepsis-induced muscle weakness was exacerbated in LCT mice, while muscle force was comparable between TPN-treated and gLCT mice (TPN 60.9%; gLCT 60.9%; LCT 33.1% of HC 128.7 mN/mm2, p < 0.001). The decrease in muscle glycolytic metabolites in LCT mice relative to TPN-treated mice was attenuated by supplemental glucose. In study 2, unexpectedly, ketosis was similarly low in gLCT and gMCT mice (p = 0.1), and muscle force was equally reduced in all septic groups (TPN 68.1%; gLCT 74.0%; gMCT 65.9% of HC 105.9 mN/mm2, p = 0.5) as compared to HC mice. Protein expression of the rate-limiting enzyme of ketogenesis, Hmgcs2, was suppressed in gMCT as compared to gLCT mice (p = 0.04).

Conclusions

Pure LCT infusion induced ketosis, but aggravated muscle weakness, which was attenuated by providing supplemental glucose. Combined with glucose, neither long-chain triglycerides nor mixed medium- and long-chain triglycerides were able to induce adequate ketosis or attenuate sepsis-induced muscle weakness.